In severe alcohol-associated liver disease with limited documented abstinence, what prospectively measurable psychosocial signals are sufficient for you to support expedited listing (treatment engagement, insight, caregiver reliability, objective toxicology strategy), and which findings reliably predict unacceptable relapse risk in your experience?